Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Roche

‘Game-changing’ new Alzheimer’s drug could slow progression of disease

There are currently estimated to be 982,000 people with some form of dementia, including Alzheimer's in the UK

The Independent UK

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe

Sarepta Therapeutics' brutal week continued Friday after European officials rejected the company's controversial gene therapy, Elevidys.

Investors Business Daily

New antibiotic that could save millions of lives enters final testing

IN FULL

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

New ‘superbug’ antibiotic to treat sepsis and pneumonia enters last phase of testing

It is hoped that the drug zosurabalpin will be approved by the end of the decade

The Independent UK

3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.

See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.

MarketBeat

US drug firm Merck says existing Trump tariffs will cost it $200m this year

Company’s forecast does not account for threatened ‘major’ tariff that could also be levied on pharmaceutical imports

The Guardian - UK

Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed

Roche beat first-quarter sales expectations Thursday, while Sanofi's sales report came in mixed. Shares were muted in premarket trades.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Swiss pharma giant Roche pledges to invest €47 billion in the US

The investment plans include new R&D sites in four US states and creating more than 12,000 jobs, according to the Swiss pharmaceutical company.

Euronews

Roche Says Will Invest $50 Bn In US, As Tariff War Uncertainty Swells

Trump's administration is blowing hot and cold on pharmaceutical products, which initially benefited from exemptions in the round of tariffs announced on April 2.

Latin Times

Swiss drugmaker Roche leans into Trump tariff formula with $50bn promise to invest in U.S.

Roche promised that its investments in the U.S. means it will export more medicines than it imports in the U.S.

Fortune

Swiss drugmaker Roche to invest $50bn in US in effort to dodge Trump tariffs

Company says it will create 12,000 jobs in manufacturing and R&D over next five years

The Guardian - UK

Roche Says Will Invest $50 Bn In US Over Next Five Years

The firm already has plants in the United States, and said the move would help expand capacity at sites in Kentucky, Indiana, New Jersey, Oregon and California.

International Business Times

IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche

TG Therapeutics rallied Wednesday after Roche's rival multiple sclerosis treatment, Ocrevus, missed its mark in a study.

Investors Business Daily

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Bayer CEO Bill Anderson on diversity initiatives, new menopause drugs and taming a runaway bureaucracy

Bayer's teams run on 90-day cycles, so the clock is always ticking on delivering on their goals.

Investors Business Daily

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investors Business Daily

Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease

Prothena stock catapulted Thursday after the company's Roche-partnered Parkinson's treatment showed promise in a midstage study.

Investors Business Daily

Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone Else

Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its weight-loss drug.

Get all your
news in one place.

100’s of premium titles.
One news app.

inkl

How Healthcare Leader Clara Latorre is Transforming Dermatology and Oncology Through Strategic Innovation

In today’s fast-paced healthcare world, few leaders balance clinical expertise and strategic innovation as seamlessly as Dr. Clara Latorre.

Benzinga

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details

Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic malignancies and solid tumors.

Benzinga

Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket

Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal.

Evening Standard

Blood test could ‘reliably rule out’ Alzheimer’s, trial finds

There are hopes it will offer reassurance to patients with cognitive decline and help them avoid unnecessary further testing, researchers said.

Investors Business Daily

Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales Expectations

Roche stock jumped Wednesday after the pharma giant reported light third-quarter sales but kept its 2024 outlook.

Investors Business Daily

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

The three-horse race to treat a devastating form of muscular dystrophy is now down to two. And Avidity Biosciences is feeling bullish.

Investors Business Daily

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.